DREAM III期研究:口服紫杉醇DHP107对比静脉紫杉醇二线治疗晚期胃癌的疗效与安全性
DREAM是一项多中心、开放标签、前瞻性随机III期研究,纳入236例一线化疗失败的晚期胃癌患者,1:1随机接受口服DHP107或静脉紫杉醇治疗。主要终点无进展生存期(PFS)非劣效性成立(HR=0.85,95%CI 0.64-1.13),总生存期(OS)和客观缓解率(ORR)组间可比,安全性谱不同但总体可控。
要点
- 口服DHP107二线治疗晚期胃癌的PFS非劣效于静脉紫杉醇(HR=0.85,95%CI 0.64-1.13)。
- DHP107组恶心、呕吐、腹泻和黏膜炎更常见,静脉紫杉醇组周围神经病变更常见。
- DHP107是首个在晚期胃癌治疗中证实疗效与安全性的口服紫杉醇制剂。
核心结论
- DHP107作为晚期胃癌二线治疗,PFS非劣效于静脉紫杉醇,其他疗效和安全性参数相当。
- DHP107是首个在晚期胃癌治疗中证实疗效与安全性的口服紫杉醇。
研究设计与样本
- 多中心、开放标签、前瞻性、随机III期研究,纳入组织学/细胞学确诊的不可切除/复发晚期胃癌一线治疗失败患者。
- 患者1:1随机接受DHP107(200 mg/m2口服,每日两次,第1、8、15天,每4周)或静脉紫杉醇(175 mg/m2,第1天,每3周)。
- 按ECOG体能状态、疾病状态和既往治疗分层,每6周采用RECIST评估疗效。
- 主要终点为PFS非劣效性,次要终点为ORR、OS和安全性。
- 共236例患者随机分组(每组n=118)。
主要发现
- 符合方案集的中位PFS:DHP107组3.0个月(95%CI 1.7-4.0),静脉紫杉醇组2.6个月(95%CI 1.8-2.8),HR=0.85(95%CI 0.64-1.13)。
- 独立中心评审的PFS敏感性分析结果相似(HR=0.93,95%CI 0.70-1.24)。
- 全分析集中位OS:DHP107组9.7个月(95%CI 7.1-11.5),静脉紫杉醇组8.9个月(95%CI 7.1-12.2),HR=1.04(95%CI 0.76-1.41)。
- ORR:DHP107组17.8%(CR 4.2%;PR 13.6%),静脉紫杉醇组25.4%(CR 3.4%;PR 22.0%)。
- DHP107组恶心、呕吐、腹泻和黏膜炎更常见;静脉紫杉醇组周围神经病变更常见;≥3级不良事件少见,最常见为中性粒细胞减少(42% vs 53%),发热性中性粒细胞减少少见(5.9% vs 2.5%);DHP107组无过敏反应(静脉紫杉醇组2.5%)。
关键数值与推荐
- 主要终点PFS非劣效性依次采用1.48和1.25的非劣效界值进行序贯检验。
- DHP107组中位PFS 3.0个月(95%CI 1.7-4.0),静脉紫杉醇组2.6个月(95%CI 1.8-2.8),HR=0.85(95%CI 0.64-1.13)。
- DHP107组中位OS 9.7个月(95%CI 7.1-11.5),静脉紫杉醇组8.9个月(95%CI 7.1-12.2),HR=1.04(95%CI 0.76-1.41)。
- ORR:DHP107组17.8%,静脉紫杉醇组25.4%。
- ≥3级中性粒细胞减少:DHP107组42%,静脉紫杉醇组53%;发热性中性粒细胞减少:5.9% vs 2.5%。
临床怎么用
- DHP107可作为晚期胃癌二线治疗的口服紫杉醇选择,PFS非劣效于静脉紫杉醇。
- 临床选择时需考虑安全性谱差异:口服DHP107消化道不良反应更多,静脉紫杉醇神经毒性更多。
- DHP107无过敏反应报告,可能简化给药流程,但需结合患者个体情况评估。
局限性
- 研究为开放标签设计,可能影响主观终点评估。
- 样本量有限(236例),需更大样本验证。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paclitaxel is currently only available as an intravenous (i.v.) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to i.v. paclitaxel as a second-line therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure. METHODS AND MATERIALS: Patients were randomized 1 : 1 to DHP107 (200 mg/m2 orally twice daily days 1, 8, 15 every 4 weeks) or i.v. paclitaxel (175 mg/m2 day 1 every 3 weeks). Patients were stratified by Eastern Cooperative Oncology Group performance status, disease status, and prior treatment; response was assessed (Response Evaluation Criteria in Solid Tumors) every 6 weeks. Primary end point: non-inferiority of progression-free survival (PFS); secondary end points: overall response rate (ORR), overall survival (OS), and safety. For the efficacy analysis, sequential tests for non-inferiority were carried out, first with a non-inferiority margin of 1.48, then with a margin of 1.25. RESULTS: Baseline characteristics were balanced in the 236 randomized patients (n = 118 per arm). Median PFS (per-protocol) was 3.0 (95% CI 1.7-4.0) months for DHP107 and 2.6 (95% CI 1.8-2.8) months for paclitaxel (hazard ratio [HR] = 0.85; 95% CI 0.64-1.13). A sensitivity analysis on PFS using independent central review showed similar results (HR = 0.93; 95% CI 0.70-1.24). Median OS (full analysis set) was 9.7 (95% CI 7.1 - 11.5) months for DHP107 versus 8.9 (95% CI 7.1-12.2) months for paclitaxel (HR = 1.04; 95% CI 0.76-1.41). ORR was 17.8% for DHP107 (CR 4.2%; PR 13.6%) versus 25.4% for paclitaxel (CR 3.4%; PR 22.0%). Nausea, vomiting, diarrhea, and mucositis were more common with DHP107; peripheral neuropathy was more common with paclitaxel. There were only few Grade≥3 adverse events, most commonly neutropenia (42% versus 53%); febrile neutropenia was reported infrequently (5.9% versus 2.5%). No hypersensitivity reactions occurred with DHP107 (paclitaxel 2.5%). CONCLUSIONS: DHP107 as a second-line treatment of AGC was non-inferior to paclitaxel for PFS; other efficacy and safety parameters were comparable. DHP107 is the first oral paclitaxel with proven efficacy/safety for the treatment of AGC. CLINICALTRIALS.GOV: NCT01839773.
引用
- Kang YK, Ryu MH, Park SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018. PMID: 29438463. doi:10.1093/annonc/mdy055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。